Actively Recruiting
Open-Label Study Comparing Tasurgratinib Pharmacokinetics in Adults With Mild and Moderate Liver Impairment Versus Healthy Adults
Led by Eisai Co., Ltd. · Updated on 2026-09-17
18
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating how mild and moderate liver impairment affect the way the body processes tasurgratinib, a drug given as a single dose. The study compares participants with different levels of liver function to healthy individuals to understand tasurgratinibs behavior in these groups. This is a Phase 1 study sponsored by Eisai Co., Ltd. focused on pharmacokinetics, which is how the drug and its metabolite move through the body. Participants with mild liver impairment will take a single 35 mg tablet of tasurgratinib after fasting overnight, while those with moderate liver impairment will receive a lower 10 mg dose given as two 5 mg capsules under similar fasting conditions. Healthy participants matched by age, race, gender, and body weight will take the same 35 mg tablet dose. All participants take the drug once in the morning with water. During the study, participants will be monitored closely over 144 hours after dosing to measure drug levels in the blood, including maximum concentration, area under the concentration curve, and other pharmacokinetic properties. The study includes safety assessments like physical exams and ECGs. Participation involves a single dosing visit and blood sampling over several days, with the total study duration lasting up to a few days post-dose.
CONDITIONS
Brief Title
Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
Research Team
I
Inquiry Service.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here